Systematic screening of viral and human genetic variation identifies antiretroviral resistance and immune escape link

Elife. 2021 Jun 1:10:e67388. doi: 10.7554/eLife.67388.

Abstract

Background: Considering the remaining threat of drug-resistantmutations (DRMs) to antiretroviral treatment (ART) efficacy, we investigated how the selective pressure of human leukocyte antigen (HLA)-restricted cytotoxic T lymphocytes drives certain DRMs' emergence and retention.

Methods: We systematically screened DRM:HLA class I allele combinations in 3997 ART-naïve Swiss HIV Cohort Study (SHCS) patients. For each pair, a logistic regression model preliminarily tested for an association with the DRM as the outcome. The three HLA:DRM pairs remaining after multiple testing adjustment were analyzed in three ways: cross-sectional logistic regression models to determine any HLA/infection time interaction, survival analyses to examine if HLA type correlated with developing specific DRMs, and via NetMHCpan to find epitope binding evidence of immune escape.

Results: Only one pair, RT-E138:HLA-B18, exhibited a significant interaction between infection duration and HLA. The survival analyses predicted two pairs with an increased hazard of developing DRMs: RT-E138:HLA-B18 and RT-V179:HLA-B35. RT-E138:HLA-B18 exhibited the greatest significance in both analyses (interaction term odds ratio [OR] 1.169 [95% confidence interval (CI) 1.075-1.273]; p-value<0.001; survival hazard ratio 12.211 [95% CI 3.523-42.318]; p-value<0.001). The same two pairs were also predicted by netMHCpan to have epitopic binding.

Conclusions: We identified DRM:HLA pairs where HLA presence is associated with the presence or emergence of the DRM, indicating that the selective pressure for these mutations alternates direction depending on the presence of these HLA alleles.

Funding: Funded by the Swiss National Science Foundation within the framework of the SHCS, and the University of Zurich, University Research Priority Program: Evolution in Action: From Genomes Ecosystems, in Switzerland.

Keywords: HIV; HLA; epidemiology; global health; human; infectious disease; microbiology; mutations.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Retroviral Agents / therapeutic use*
  • Cross-Sectional Studies
  • Drug Resistance, Viral / genetics*
  • Drug Resistance, Viral / immunology
  • Female
  • Genome, Human*
  • Genome, Viral*
  • HIV Infections / drug therapy*
  • HIV Infections / genetics
  • HIV Infections / immunology
  • HIV Infections / mortality
  • HLA Antigens / genetics*
  • HLA Antigens / immunology
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Mutation Rate
  • Mutation*
  • Prospective Studies
  • Risk Assessment
  • Risk Factors
  • Switzerland
  • T-Lymphocytes, Cytotoxic / immunology*
  • Treatment Outcome

Substances

  • Anti-Retroviral Agents
  • HLA Antigens

Grants and funding

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.